Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERANT: Low Dose Tamoxifen and Lifestyle Changes for Breast Cancer Prevention
NCT06033092Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen in breast cancer, sponsored by European Institute of Oncology. Started Jun 2024; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06033092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033092.